Literature DB >> 12401309

HFE Mutations as risk factors in disease.

Mark Worwood1.   

Abstract

Iron deficiency is the most common disorder of iron metabolism worldwide, but there is concern that iron accumulation resulting from enhanced iron absorption may also be a cause of morbidity. In patients with genetic haemochromatosis the clinical manifestations of iron overload are well-known. In northern Europe 90% of such patients are homozygous for the C282Y mutation of the HFE gene and this genotype is found in 1 in 200 of the population. Heterozygosity for C282Y occurs in 15% of the population and 25% carry another mutation, H63D. Population studies have revealed (i) the serum transferrin saturation is strongly influenced by HFE genotype, being lowest in subjects lacking mutations and highest in those homozygous for C282Y; (ii) most subjects homozygous for C282Y accumulate iron but do not present with the clinical manifestations of iron overload. Testing for HFE mutations in clinics for diabetes, liver disease and cardiovascular disease has shown that homozygosity for C282Y is not commonly found. Heterozygosity for either C282Y or H63D does not appear to be a risk factor for these common conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12401309

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  8 in total

1.  Longevity and carrying the C282Y mutation for haemochromatosis on the HFE gene: case control study of 492 French centenarians.

Authors:  Hélène Coppin; M Bensaid; S Fruchon; N Borot; H Blanché; M P Roth
Journal:  BMJ       Date:  2003-07-19

2.  Heterozygosity for the haemochromatosis mutation HFE C282Y is not a risk factor for angina.

Authors:  G P Feeney; P A L Ashfield-Watt; M L Burr; F D J Dunstan; I F W McDowell; M Worwood
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

3.  Heteroduplex analysis for the three common HFE variants: methodology, reliability and analysis of over 5000 requests for testing.

Authors:  Jeanne Kingston; Derrick Bowen; Marion Sweeney; Susan Lawless; Helen Jackson; Mark Worwood
Journal:  J Clin Pathol       Date:  2006-11-01       Impact factor: 3.411

4.  Targeted screening for genetic haemochromatosis: a combined phenotype/genotype approach.

Authors:  M Bhavnani; D Lloyd; J Marples; K Pendry; M Worwood
Journal:  J Clin Pathol       Date:  2006-05       Impact factor: 3.411

5.  Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients.

Authors:  C A McCune; D Ravine; K Carter; H A Jackson; D Hutton; J Hedderich; M Krawczak; M Worwood
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

Review 6.  Non-HFE hemochromatosis: genetics, pathogenesis, and clinical management.

Authors:  James E Nelson; Kris V Kowdley
Journal:  Curr Gastroenterol Rep       Date:  2005-02

7.  Four variants in transferrin and HFE genes as potential markers of iron deficiency anaemia risk: an association study in menstruating women.

Authors:  Ruth Blanco-Rojo; Carlos Baeza-Richer; Ana M López-Parra; Ana M Pérez-Granados; Anna Brichs; Stefania Bertoncini; Alfonso Buil; Eduardo Arroyo-Pardo; Jose M Soria; M Pilar Vaquero
Journal:  Nutr Metab (Lond)       Date:  2011-10-06       Impact factor: 4.169

8.  Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.

Authors:  P Valent; O Krieger; R Stauder; F Wimazal; T Nösslinger; W R Sperr; H Sill; P Bettelheim; M Pfeilstöcker
Journal:  Eur J Clin Invest       Date:  2008-01-24       Impact factor: 4.686

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.